



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Public Declaration of Interests and Confidentiality Undertaking of
European Medicines Agency (EMA),
Scientific Committee members and experts

Public declaration of interests

I, **Samuel Abbou**

Organisation/Company: Gustave Roussy

Country: France

do hereby declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical industry are those listed below:

2.1 Employment

No interest declared

2.2 Consultancy

No interest declared

2.3 Strategic advisory role

No interest declared

2.4 Financial interests

No interest declared

2.5 Principal investigator

Period	Company	Products	Therapeutic Indication
01/2021-(current)	Orphelia	Temokids	oral suspension for temozolomide, basket trial

2.6 Investigator

Classified as public by the European Medicines Agency

Period	Company	Products	Therapeutic Indication
09/2020-(current)	MSD	Lenvatinib	basket trial, phase 2, children with relapsed or refractory solid tumor

2.7 Grant / Funding to organisation /institution

No interest declared

2.8 Close family member interest

No interest declared

2.9 Repurposing of a medicinal product

No interest declared

2.10 Any other interests or facts

Here the list of academic trials i am participating to as a sub investigator.

E-smart trial : basket trial with several arms.

BEACON Children and young adults aged 1 to 21 years of age with relapsed/refractory neuroblastoma.

LINES: upfront neuroblastoma

MUCILA: laser for mucositis

HRNBL2: high risk neuroblastoma

OVIMA PROGRESSIVE OR RECURRENT UNRESECTABLE LOW-GRADE GLIOMA II oral navelbine

PHITT-SIOPEL 7 "Paediatric Hepatic International Tumour Trial ; Patients ?30 years of age with newly diagnosed hepatic cancers: primary paediatric hepatic malignancies HB and hepatocellular carcinoma HCC"

PNET 5 (PHASE II) "CLINICALLY STANDARD-RISK MEDULLOBLASTOMAIN CHILDREN OLDER THAN 3 TO 5 YEARS WITHLOW-RISK BIOLOGICAL PROFILE (PNET 5 MB - LR)OR AVERAGE-RISK BIOLOGICAL PROFILE (PNET 5MB -SR)"

rECCUR Recurrent and Primary Refractory Ewing Sarcoma

SARCOME 13 - OS 2016 "Phase 2 trial of mifamurtide combined with post-operative chemotherapyfor newly diagnosed high risk osteosarcoma patients(metastatic osteosarcoma at diagnosis or localised disease with poor histological response)"

SIOP EPENDYMOME II "diagnosis and treatmentof children, adolescents and young adults with ependymoma"

TGM 2013 : Malignant germinal tumors

UMBRELLA Enfants atteints de tumeurs rénales

VERITAS "evaluating and comparing two intensification treatmentstrategies for metastatic neuroblastoma patients with a poorresponse to induction chemotherapy"

NIVO-ALCL BMS pediatric and adult relapsing/refractory ALK+ anaplastic large cell lymphoma

NIVOGLIO BMS upfront pediatric and adolescent glioblastoma

REGORAFENIB (REGOBONE) ? 10 yo, relapse/refractory_ RANDOMISATION Rego/Placebo

2.11 CAT member or alternate

No interest declared

CONFIDENTIALITY UNDERTAKING

In view of the following definitions:

"EMA Activities" encompass any meeting (including meeting preparation and follow-up, associated discussion or any other related activity) of the European Medicines Agency's Management Board, Committees, Working Parties, Expert

Classified as public by the European Medicines Agency

Groups, or any other such meeting; work as an expert on assessments; work as an expert on guidance development.

"Confidential Information" means all information, facts, data and any other matters of which I acquire knowledge, either directly or indirectly, as a result of my EMA Activities.

"Confidential Documents" mean all drafts, preparatory information, documents and any other material, together with any information contained therein, to which I have access, either directly or indirectly, as a result of my participation in EMA Activities. Furthermore, any records or notes made by me relating to Confidential Information or Confidential Documents shall be treated as Confidential Documents.

I understand that I may be invited to participate either directly or indirectly in certain EMA activities and hereby undertake:

- To treat all Confidential Information and Confidential Documents under conditions of strict confidentiality as long as the information or document has not been made public/is not in the public domain.
- Not to disclose (or authorise any other person to disclose) in any way to any third party any Confidential Information or Confidential Document.
- Not to use (or authorise any other person to use) any Confidential Information or Confidential Document other than for the purposes of my work in connection with EMA activities.
- To dispose of Confidential Documents as confidential material as soon as I have no further use for them.
- When expressing views to clearly indicate that the views are my own if acting in my own capacity or those of the EMA, Committee, Working Party, Expert Group or other group if acting on behalf that group.
- Not to disclose any commercially confidential information.

This undertaking shall not be limited in time, but shall not apply to any document or information that I can reasonably prove was known to me before the date of this undertaking or which becomes public knowledge other than as a result of a breach of any of the above undertakings.

I confirm the information declared on this form is accurate to the best of my knowledge and I acknowledge that my information will be stored electronically and published on the EMA website.

Full Name:	Samuel Abbou
Date:	2021-02-03

For Definitions of activities etc, refer to Policy on Handling of competing interests / Electronic DOI template